Lynx1 Capital Management LP disclosed a 21.0% stake in Passage BIO, Inc. common stock. The firm filed a Schedule 13D on Jul. 02, 2026 after moving from a passive 13G because its ownership crossed 20%. The shift signals a more active posture as Passage BIO moves to merge with Remix Therapeutics.

Investor Intent

Lynx1 agreed to join a concurrent financing tied to Passage BIO’s merger with Remix Therapeutics, buying Remix common stock and convertible notes and securing registration rights for resale. The fund expects to receive additional Passage BIO shares at the merger’s effective time and will also receive one contingent value right per Passage BIO share held before closing.

Lynx1 may discuss business strategy, capital structure, governance, and the merger with company leaders and other investors. "We expect to receive additional Passage BIO shares when the Remix merger closes," and "We may talk with management and other shareholders about strategy and the merger."

Investor's Background

Lynx1 Capital Management LP is a Delaware limited partnership that serves as the investment manager to Lynx1 Master Fund LP. Chief Investment Officer Weston Nichols oversees the firm’s portfolio decisions. The firm focuses on public equities and event-driven situations, often taking concentrated positions and engaging on strategic outcomes.

Original SEC Filing: Passage BIO, Inc. [ PASG ] - SCHEDULE 13D - Jul. 02, 2026